ID   UMT2
AC   CVCL_R739
SY   Uveal Melanoma Tubingen 2
DR   cancercelllines; CVCL_R739
DR   Cosmic; 1879475
DR   Wikidata; Q54991137
RX   PubMed=23456173;
RX   PubMed=27505446;
CC   Group: Serum/protein free medium cell line.
CC   Doubling time: 3-4 days (PubMed=23456173).
CC   Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=23456173).
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 05-10-23; Version: 14
//
RX   PubMed=23456173; DOI=10.1007/s00417-013-2292-9;
RA   Susskind D., Gauss S., Faust U.E.A., Bauer P., Schrader M.,
RA   Bartz-Schmidt K.-U., Henke-Fahle S.;
RT   "Characterisation of novel uveal melanoma cell lines under serum-free
RT   conditions.";
RL   Graefes Arch. Clin. Exp. Ophthalmol. 251:2063-2070(2013).
//
RX   PubMed=27505446; DOI=10.1111/ceo.12814;
RA   Susskind D., Hurst J., Rohrbach J.M., Schnichels S.;
RT   "Novel mouse model for primary uveal melanoma: a pilot study.";
RL   Clin. Exp. Ophthalmol. 45:192-200(2017).
//